Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  OncoTarget

• Publication date

  2017-08-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.13386PMID 27907905PMCID PMC5581022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma

  2016cited by this paper
• Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

  2016cited by this paper
• Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer

  2015cited by this paper
• Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma

  2015cited by this paper
• Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

  2015cited by this paper
• Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

  2015cited by this paper
• Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

  2015influential reference
• Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo

  2014cited by this paper
• The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.

  2014influential reference
• PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment.

  2014cited by this paper
• Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in 12 V-Ha-Ras transgenic mouse glioma model

  2014cited by this paper
• Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

  2013influential reference
• Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.

  2013influential reference
• Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy

  2013influential reference
• Targeting epigenetic readers in cancer.

  2012cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

  2012cited by this paper
• Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  2012influential reference
• BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

  2012cited by this paper
• Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma

  2012cited by this paper
• MYC on the path to cancer.

  2012cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011cited by this paper
• Bromodomains as therapeutic targets

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011influential reference
• αV integrins in angiogenesis and cancer.

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Recent advances in neuroblastoma.

  2010cited by this paper
• Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

  2009cited by this paper
• PTEN and the PI3-kinase pathway in cancer.

  2009cited by this paper
• The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

  2009cited by this paper
• A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

  2008influential reference
• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

  2008cited by this paper
• Activation of Akt predicts poor outcome in neuroblastoma.

  2007cited by this paper
• Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

  2006cited by this paper
• The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.

  2006cited by this paper
• Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma

  2004cited by this paper
• The regulation of angiogenesis in neuroblastoma.

  2003cited by this paper
• PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.

  2003cited by this paper
• Hypomethylation and hypermethylation of DNA in Wilms tumors

  2002cited by this paper
• Considerations when analyzing the methylation status of PTEN tumor suppressor gene.

  2002cited by this paper
• Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist

  2001cited by this paper
• DNA methylation analysis by MethyLight technology.

  2001cited by this paper
• PTEN controls tumor-induced angiogenesis

  2001cited by this paper
• Analysis of PTEN/MMAC1 alteration in neuroblastoma.

  2001cited by this paper
• Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.

  2000influential reference
• Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model.

  2000cited by this paper
• A mechanism for modulation of cellular responses to VEGF: activation of the integrins.

  2000cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

  1999cited by this paper
• Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

  1999cited by this paper
• Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.

  1998cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.

  1996cited by this paper
• Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma.

  1996cited by this paper
• Definition of two angiogenic pathways by distinct alpha v integrins.

  1995cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper
• Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

  1994cited by this paper
• Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy

  1991cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour

  1983cited by this paper
• Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank

  year unknowncited by this paper

• Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma

  2023cites this paper
• Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review

  2023cites this paper
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• Neuroblastoma: Essential genetic pathways and current therapeutic options.

  2022cites this paper
• Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma.

  2021cites this paper
• Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells

  2021cites this paper
• BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma

  2021cites this paper
• Advances in pharmacotherapy for neuroblastoma

  2021cites this paper
• CD146 is a potential immunotarget for neuroblastoma

  2021cites this paper
• MYCN in Neuroblastoma: “Old Wine into New Wineskins”

  2021cites this paper
• Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma

  2021cites this paper
• Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs

  2021cites this paper
• Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions

  2020influential citation
• The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives

  2020cites this paper
• The E3 ubiquitin ligase NEDD4 mediates EGFR-TKI acquired resistance in non-small cell lung cancer

  2019cites this paper
• Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

  2019cites this paper
• Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

  2019cites this paper
• Neuroblastoma: clinical and biological approach to risk stratification and treatment

  2018cites this paper
• Neuroblastoma: clinical and biological approach to risk stratification and treatment

  2018cites this paper
• A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers

  2017cites this paper